{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field 2a2fe668-e4a5-45e0-a1bb-a374209e8386 --><h2>Doxycycline</h2><!-- end field 2a2fe668-e4a5-45e0-a1bb-a374209e8386 -->","summary":"","htmlStringContent":"<!-- begin item 260d0fa7-1dcc-451b-a5f6-61dfa7c9ebc5 --><!-- end item 260d0fa7-1dcc-451b-a5f6-61dfa7c9ebc5 -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ae47a3aa-d831-5c55-872c-f2c98d3a65a9","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f2c33e63-e201-4572-8003-a9470131bf33 --><h3>What are the contraindications and cautions?</h3><!-- end field f2c33e63-e201-4572-8003-a9470131bf33 -->","summary":"","htmlStringContent":"<!-- begin item 811345f2-ebeb-4ef2-9a7a-a9470131bdd3 --><!-- begin field 67fe834b-db8c-4b9a-8b60-a9470131bf37 --><ul><li><strong>Do not prescribe doxycycline to:</strong><ul><li>People with:<ul><li>Known hypersensitivity to any of the tetracyclines.</li><li>Acute porphyria.</li><li>Systemic lupus erythematous — tetracyclines may exacerbate systemic lupus erythematosus.</li></ul></li><li>Pregnant and breastfeeding women — doxycycline is deposited in the teeth and bones of unborn or developing children. The British National Formulary (BNF) advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]:<ul><li>Tetracyclines should be avoided during pregnancy because effects on skeletal development have been documented in the first trimester in animal studies, and administration during the second or third trimester may cause discoloration of the child’s teeth.</li><li>Tetracyclines should be avoided during breast feeding, although absorption and therefore discoloration of teeth in the infant is probably usually prevented by chelation with calcium in milk.</li></ul></li><li>Children aged under 12 years — deposition in growing bone and teeth, by binding to calcium, causes staining and occasionally dental hypoplasia.</li></ul></li><li><strong>Prescribe </strong><strong>doxycycline</strong><strong> with caution to: </strong><ul><li>People with:<ul><li>Myasthenia gravis — tetracyclines may increase muscle weakness in people with myasthenia gravis.</li><li>Hepatic impairment — avoid if possible.</li><li>Renal impairment — avoid excessive doses.</li></ul></li><li>People likely to be exposed to direct sunlight or ultraviolet light — photosensitivity manifested by an exaggerated sunburn reaction has been observed in some people taking tetracyclines, including doxycycline. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 67fe834b-db8c-4b9a-8b60-a9470131bf37 --><!-- end item 811345f2-ebeb-4ef2-9a7a-a9470131bdd3 -->","subChapters":[]},{"id":"3380afdd-58d6-57ac-a86c-c68101099749","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 0fabc9ce-0137-40e8-9a73-a9470132106a --><h3>What are the adverse effects?</h3><!-- end field 0fabc9ce-0137-40e8-9a73-a9470132106a -->","summary":"","htmlStringContent":"<!-- begin item 8faf497e-cf69-4d92-8c55-a94701320f2b --><!-- begin field 5d191268-0dc9-4dc0-a0cb-a9470132106a --><ul><li><strong>Adverse effects of doxycycline include:</strong><ul><li>Anorexia, anxiety, dry mouth, flushing, fungal superinfection (when used for periodontitis), and tinnitus.</li></ul></li><li><strong>Adverse effects of all tetracyclines include:</strong><ul><li><strong>Rare </strong>— blood disorders, exfoliative dermatitis, hepatotoxicity, pancreatitis, pericarditis, anaphylaxis, angioedema, hypersensitivity reactions, rash, Stevens-Johnson syndrome, urticaria, and photosensitivity (advise people taking doxycycline to avoid exposure to direct sunlight or to sunlamps).</li><li><strong>Frequency not known </strong>— antibiotic-associated colitis, benign intracranial hypertension, headache and visual disturbance (may indicate benign intracranial hypertension. Discontinue treatment if these occur), diarrhoea, dysphagia, nausea, vomiting, and oesophageal irritation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 5d191268-0dc9-4dc0-a0cb-a9470132106a --><!-- end item 8faf497e-cf69-4d92-8c55-a94701320f2b -->","subChapters":[]},{"id":"6f16d850-a2c9-5184-ad76-23571020990e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8e826077-2086-4b7c-abb6-a94701322a84 --><h3>What are the drug interactions?</h3><!-- end field 8e826077-2086-4b7c-abb6-a94701322a84 -->","summary":"","htmlStringContent":"<!-- begin item 84d099ce-e7c5-40f5-ad1f-a94701322981 --><!-- begin field ba14c023-4765-45d9-9d15-a94701322a84 --><ul><li><strong>Drug interactions of doxycycline include:</strong><ul><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc</strong> — these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Advise the person to avoid taking antacids and other medications containing iron or zinc 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>CYP3A enzyme inducers</strong> <strong>(phenobarbital, carbamazepine or phenytoin)</strong> — these may reduce the serum half-life of doxycycline.<ul><li>Monitor and adjust the dose if necessary.</li></ul></li><li><strong>Insulin</strong> — the blood-glucose lowering effect of insulin may be increased if taken with doxycycline.<ul><li>Monitor blood glucose levels.</li></ul></li><li><strong>Lithium</strong> — levels may be increased by doxycycline.<ul><li>Consider increasing the frequency of lithium monitoring.</li></ul></li><li><strong>Methotrexate</strong> — levels may be increased by doxycycline. </li><li><strong>Retinoids</strong> — there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid concurrent use.</li></ul></li><li><strong>Rifampicin</strong> — doxycycline levels may be markedly reduced, which may lead to treatment failure.<ul><li>Monitor the effects and increase doxycycline dose if necessary.</li></ul></li><li><strong>Warfarin</strong> — the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect. However, there is little evidence to suggest clinical relevance.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not</em> required during or after courses of doxycycline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>doxycycline</strong><strong><strong>,</strong> </strong>see the <a data-hyperlink-id=\"5203f819-92f2-4ec0-b745-a94a00ee63e5\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"3eb72c95-6193-4a8b-81f0-a94a00ee64a5\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field ba14c023-4765-45d9-9d15-a94701322a84 --><!-- end item 84d099ce-e7c5-40f5-ad1f-a94701322981 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}